Strategies to increase pancreatic β-cell mass and function

Amedeo Vetere, Amit Choudhary & Bridget K. Wagner

September 2013

Although the underlying causes of type 1 and type 2 diabetes differ, reduced insulin-producing pancreatic β-cell mass is a central feature of both forms of the disease. However, few existing diabetes drugs are effective at protecting or restoring β-cells in patients. This poster illustrates small-molecule approaches that are currently being investigated to therapeutically increase β-cell mass and function, including the induction of β-cell proliferation and insulin secretion, the reprogramming of closely related cell types to β-cells, or protection from apoptosis.

Extra navigation

Supported by

Novo Nordisk